Matthew Weinberg Writes for International Clinical Trials (ICT) Magazine
August 16, 2013
In this article CEO Matthew Weinberg discusses the downsides to self-auditing good clinical practice and the need smaller, more proactive audits, on the other hand, can provide a more intelligent analysis.
Subscribe for Updates
April 23, 2012
CEO Matthew Weinberg Presents at FDA Clinical Trials Hearing
April 23 - The Weinberg Group CEO, Matthew Weinberg, presented today at FDA’s hearing titled “Modernizing the Regulation of Clinical Trials and Approaches to Good Clinical Practice.” Mr. Weinberg...
Mydecine Innovations Group Engages ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials
DENVER, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research,...